CURE OM Steering Committee
The CURE OM Steering Committee is responsible for planning educational events and providing guidance and expertise for the CURE OM initiative. This collaborative international committee, composed of patients, caregivers, scientists, doctors, and MRF staff, is dedicated to improving the experience of people diagnosed with ocular melanoma. View the members of the CURE OM Scientific Steering Committee.
Sara M. Selig, MD
CURE OM Director, Melanoma Research Foundation
Department of Internal Medicine, Brigham and Women's Hospital
Sara's husband was diagnosed with a primary ocular melanoma in 2006 at the age of 34 and with metastatic disease in 2007. He lost his battle to the disease in 2012. Dr. Selig also sits on the CURE OM Scientific Steering Committee.
CURE OM Program Manager, Melanoma Research Foundation
Lauren came to the MRF in 2015 after her friend was diagnosed with a recurrence of OM the previous year. She has become a strong OM patient advocate and support for both patients and caregivers.
London, United Kingdom
Robert’s spouse was diagnosed with ocular melanoma in 2010.
Esther Damaser, PhD
Yellow Springs, Ohio
Esther was diagnosed with ocular melanoma in 1980, and since then has been a passionate advocate for improving access to research and treatment for patients with ocular melanoma. Read Esther’s story.
Anne Marie Montijo, MSW
Anne Marie is an ocular melanoma survivor who has been part of the CURE OM Steering Committee since its inception in 2011. She's been an active leader and fundraiser in the OM community since her diagnosis in 2006. After her diagnosis, Anne Marie created a support network in the New York tri-state area, comprised of survivors and family members, which meets for luncheons at least twice each year.
Chrisi is an ocular melanoma survivor who was diagnosed with ocular melanoma in 2014. Raising awareness of this rare eye cancer is very important to her, as is helping to provide others with both support and education. She has been serving on the CURE OM Steering Committee since 2015.
Mark is an ocular melanoma survivor. He was treated for a primary tumor in July 2007. He continues to have regular follow-ups and, to day, there is no evidence of spread of the disease. Mr. Weinzierl is the founder and chairman of Anelto, a company specializing in remote telehealth and mobile emergency response devices; and founder and chairman of Zackat, Inc., a technology investment firm. He has served on the steering committee since 2011.